| 1408 |
National Cancer Institute |
Html |
en |
Grief, Bereavement, and Coping With Loss (PDQ®)–Health Professional Version |
Expert-reviewed report about grief, bereavement, and feelings of loss in survivors of someone who has died of cancer. Grief in children is also discussed. |
| normal grief process | 0.581221 |
| unanticipated grief | 0.551516 |
| IPT | 0.463911 |
| depressive symptoms | 0.559773 |
| loss | 0.542758 |
| common emotional reactions | 0.45155 |
| children | 0.526047 |
| interpersonal problems | 0.458662 |
| middle phase | 0.464448 |
| Health care providers | 0.455228 |
| grief counseling exists. | 0.565426 |
| grief | 0.933904 |
| anticipatory grief | 0.744484 |
| health care professionals | 0.481565 |
| unanticipated death differs | 0.464542 |
| exposure therapy | 0.455194 |
| bereaved people | 0.453892 |
| grief experiences | 0.564377 |
| grief reactions | 0.683036 |
| minimal grief reaction—a | 0.565 |
| age range | 0.479943 |
| grief symptoms | 0.544738 |
| deceased person | 0.466915 |
| grief intensity | 0.535236 |
|
| necessary grieving process | 0.451469 |
| social reactions | 0.450213 |
| select grief assessment | 0.557139 |
| normal grief | 0.697811 |
| death | 0.578011 |
| grief bursts | 0.548077 |
| IPT group | 0.456027 |
| cancer experience | 0.45206 |
| grieving process | 0.505158 |
| chronic grief reactions | 0.566742 |
| complicated grief | 0.62885 |
| term anticipatory grief | 0.59229 |
| health care | 0.509332 |
| common grief reactions | 0.572313 |
| pathologic grief reactions | 0.569264 |
| normal emotional process | 0.454248 |
| bereaved persons | 0.498553 |
| severe grief reactions | 0.591257 |
| grief disorder | 0.543808 |
| actual death | 0.478188 |
| grief treatment | 0.548186 |
| bereaved persons experience | 0.472239 |
| grief experience | 0.541082 |
| stage models | 0.450278 |
|
CLICK HERE |
| 1537 |
National Cancer Institute |
Html |
en |
Newcastle Disease Virus (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer. |
| metastatic tumor cells | 0.405592 |
| tumor cell lines | 0.391976 |
| human cancer cells | 0.50054 |
| genetically engineered NDV | 0.389911 |
| NDV oncolysates | 0.413317 |
| autologous tumor vaccine | 0.41773 |
| infected cells | 0.416882 |
| historical control subjects | 0.398257 |
| irradiated ESb cells | 0.39152 |
| Cancer Res | 0.395898 |
| disease virus therapy | 0.398313 |
| virus-modified tumor cells | 0.412589 |
| virus-modified autologous tumor | 0.394368 |
| autologous tumor cell | 0.439505 |
| patients | 0.465722 |
| Natl Cancer Inst | 0.401926 |
| human tumor cells | 0.440276 |
| lytic strains | 0.409693 |
| normal human cells | 0.424643 |
| cell vaccines | 0.393769 |
| et al. | 0.391296 |
| autologous tumor cells | 0.542424 |
| colorectal cancer patients | 0.390231 |
| cancer cells | 0.51627 |
| newcastle disease virus | 0.925041 |
|
| primary tumor cells | 0.39623 |
| PUBMED Abstract | 0.426283 |
| disease virus vaccine | 0.404352 |
| uninfected cancer cells | 0.394475 |
| tumor cells | 0.60365 |
| tumor cell vaccine | 0.404276 |
| progeny virus particles | 0.393227 |
| NDV | 0.533791 |
| Abstract | 0.460011 |
| human immune cells | 0.389104 |
| autologous cells | 0.393227 |
| NDV genetic material | 0.390979 |
| nonlytic NDV strains | 0.407173 |
| NDV-infected cancer cells | 0.395154 |
| malignant melanoma patients | 0.394264 |
| Human tumor cell | 0.388361 |
| renal cell carcinoma | 0.423539 |
| cells | 0.622446 |
| main NDV proteins | 0.390649 |
| ESb cells | 0.400925 |
| NDV strains | 0.410203 |
| regional lymph nodes | 0.425639 |
| cancer | 0.567906 |
| irradiated tumor cells | 0.398885 |
|
CLICK HERE |
| 1696 |
National Cancer Institute |
Html |
en |
Topics in Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version |
Expert-reviewed information summary that contains information on integrative, complementary, and/or alternative therapies for people with cancer. |
| cancer treatment | 0.500109 |
| standard treatments | 0.546145 |
| National Health Interview | 0.49394 |
| randomized controlled trials | 0.478599 |
| good manufacturing processes | 0.485786 |
| Cancer Complementary | 0.466196 |
| blood cell count | 0.487384 |
| NCI Fact Sheets | 0.492301 |
| concomitantly administered drugs | 0.486833 |
| depression management | 0.497623 |
| cancer information summary | 0.503433 |
| potentially active ingredients | 0.480985 |
| PDQ summaries | 0.45939 |
| St. John | 0.975444 |
| cancer patients | 0.494368 |
| NCI Fact | 0.496884 |
| wort | 0.678406 |
| effects | 0.47211 |
| complementary therapies | 0.460635 |
| cancer survivors | 0.459401 |
| PDQ summary section | 0.501629 |
| human immunodeficiency virus | 0.480593 |
| various metabolic enzymes | 0.481932 |
| major active constituents | 0.486518 |
| commonly treated symptoms | 0.485606 |
|
| Chinese medical therapies | 0.495937 |
| antidepressant therapy | 0.478022 |
| deep breathing exercises. | 0.492057 |
| Complementary medicine | 0.467053 |
| CAM therapies | 0.48574 |
| specific PDQ summary | 0.501712 |
| dietary supplements | 0.496339 |
| systemic concentrations | 0.461386 |
| alternative medicine | 0.659692 |
| herbal agent | 0.488319 |
| natural killer cell | 0.486571 |
| lower concentrations | 0.45956 |
| traditional Chinese medicine | 0.494167 |
| clinically important effect | 0.485748 |
| monoamine oxidase inhibitor | 0.490216 |
| PDQ summary | 0.540549 |
| randomized controlled trials. | 0.478417 |
| popular herbal agent | 0.484348 |
| NCI Fact Sheet | 0.49194 |
| major depressive disorder | 0.543366 |
| Alternative Medicine website | 0.499408 |
| sufficient concentrations | 0.46476 |
| milder depression | 0.458918 |
| cancer | 0.510149 |
|
CLICK HERE |
| 1999 |
National Cancer Institute |
Html |
es |
Tratamiento de los astrocitomas infantiles (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los astrocitomas infantiles. |
| siguientes procedimientos | 0.509449 |
| células madre | 0.756546 |
| siguientes aspectos | 0.541249 |
| efectos secundarios meses | 0.505608 |
| sustancia llamada fcev | 0.432048 |
| prueba mib-1 | 0.42502 |
| vÃa oral | 0.416944 |
| encéfalo benignos | 0.476825 |
| único tratamiento | 0.445679 |
| proteÃna cinasa.Los inhibidores | 0.434623 |
| glioma coroideo | 0.430143 |
| escasas ocasiones | 0.429534 |
| células t | 0.452739 |
| efectos tardÃos | 0.580441 |
| estrella llamadas | 0.429847 |
| PDQ Efectos tardÃos | 0.459317 |
| National Cancer Institute | 0.412326 |
| tumores benignos | 0.512758 |
| siguientes riesgos | 0.412382 |
|
| alto recién | 0.437854 |
| Instituto Nacional | 0.422716 |
| PDQ Tratamiento | 0.437378 |
| determinados cambios | 0.429353 |
| neurofibromatosis tipo | 0.592389 |
| tanta cantidad | 0.426418 |
| presente sección | 0.412644 |
| nuevos tipos | 0.4212 |
| siguientes casos | 0.43033 |
| sistema nervioso central | 0.991625 |
| Physician Data Query | 0.447246 |
| siguientes partes | 0.443422 |
| cuánto tumor | 0.508299 |
| cuerpo.ampliar derivación | 0.416932 |
| células cancerosas.Hay | 0.455449 |
| panel derecho | 0.460499 |
| siguientes sumarios | 0.465245 |
| vasos sanguÃneos | 0.616892 |
|
CLICK HERE |
| 2021 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de cuello uterino (PDQ®)–Versión para pacientes |
Información revisada por expertos sobre los factores que pueden aumentar el riesgo de cáncer de cuello uterino y los enfoques que podrían ayudar a la prevención de esta enfermedad. |
| Visuals Online | 0.544747 |
| PDQ Exámenes | 0.729141 |
| Internet NCI | 0.599334 |
| siguientes factores | 0.942852 |
| voluntarios sanos | 0.571782 |
| Physician Data Query | 0.821847 |
| Estados Unidos | 0.732136 |
| suficiente ejercicio | 0.608117 |
|
| prevención revisa | 0.577919 |
| PDQ Prevención | 0.648162 |
| cuánto tiempo | 0.58363 |
| National Cancer Institute | 0.579131 |
| invasivo aumenta | 0.607513 |
| siguientes riesgos | 0.566231 |
| siguientes sumarios | 0.745167 |
| Instituto Nacional | 0.648132 |
|
CLICK HERE |
| 3597 |
National Cancer Institute |
Html |
en |
MERIT Award Recipient: Laimonis A. Laimins, Ph.D. |
MERIT Award Recipient: Laimonis A. Laimins, Ph.D. |
| productive life cycle | 0.692492 |
| anti-viral therapies | 0.414992 |
| long-term objective | 0.415026 |
| viral particles | 0.475434 |
| viral factor | 0.465899 |
| HPV types | 0.533205 |
| Viral infection | 0.48447 |
| HPV proteins functions | 0.60071 |
| proliferative lesions | 0.427068 |
| stratified epithelial cells | 0.554619 |
| E4 protein | 0.416206 |
| small DNA viruses | 0.509754 |
| development | 0.367942 |
| life cycle | 0.732336 |
| tissue culture | 0.408683 |
| cervical cancer | 0.697893 |
| anogenital cancers | 0.416749 |
| viral replication | 0.470226 |
| pathogenesis | 0.323941 |
| certain types | 0.427907 |
| late viral functions | 0.551387 |
| HPV functions | 0.507234 |
| genetic analyses | 0.407346 |
| HPV infections | 0.62415 |
| activation | 0.321394 |
|
| productive viral life | 0.570807 |
| blocks infection | 0.430045 |
| E5 protein | 0.409072 |
| differentiation | 0.394198 |
| HPVs | 0.330868 |
| methods | 0.33537 |
| virion assembly | 0.42345 |
| genome amplification | 0.41342 |
| human papillomaviruses | 0.908593 |
| Oncogenic Papillomaviruses | 0.574563 |
| organotypic cultures | 0.4081 |
| normal cells | 0.43284 |
| suprabasal cells | 0.432461 |
| cases | 0.370169 |
| effective anti-virals | 0.431518 |
| epithelial cells | 0.561264 |
| protein synthesis | 0.412779 |
| HPV viral proteins | 0.658868 |
| vaccine | 0.388142 |
| Additional studies | 0.403147 |
| future | 0.32145 |
| cell death pathway | 0.503149 |
| high-risk types | 0.424894 |
| grant | 0.339966 |
|
CLICK HERE |
| 3653 |
National Cancer Institute |
Html |
es |
Cannabis y canabinoides (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer como la náusea y el vómito. |
| suficiente información | 0.303746 |
| American Academy | 0.304933 |
| salud masculina | 0.30438 |
| Controlled Substances Act | 0.309374 |
| estado.ampliar mapa | 0.305022 |
| NCI Best Case | 0.309795 |
| Ley Boggs | 0.304951 |
| ratones modelo | 0.329727 |
| Asia central | 0.304897 |
| datos bibliográficos pubmed | 0.306457 |
| principal canabinoide | 0.317402 |
| continuas preocupaciones | 0.305444 |
| Instituto Nacional | 0.356831 |
| distintos métodos | 0.304585 |
| Salud Complementaria | 0.311676 |
| Asociación Médica Americana | 0.308343 |
| complementarias revisa | 0.305401 |
| huésped aguda | 0.30517 |
| posibles efectos | 0.307656 |
| siglo xix | 0.305316 |
| Estados Unidos | 0.923075 |
| Investigational New Drug | 0.308776 |
| ¿Los beneficios | 0.303644 |
| Centro Nacional | 0.308445 |
| células madre | 0.307765 |
|
| New Hampshire Avenue | 0.305866 |
| creciente interés | 0.305364 |
| Drug Administration | 0.303686 |
| vÃa oral | 0.438627 |
| medicamentos canabinoides | 0.315665 |
| lista i | 0.304143 |
| Marijuana Tax Act | 0.30965 |
| Men's Health Study | 0.308077 |
| siguientes riesgos | 0.303989 |
| suficientes pruebas | 0.305693 |
| Visuals Online | 0.304212 |
| sistema nervioso central | 0.330645 |
| Physician Data Query | 0.323581 |
| libre uso | 0.304331 |
| principal ingrediente | 0.304814 |
| receptores canabinoides | 0.313898 |
| posibles beneficios | 0.304408 |
| página manejo | 0.303972 |
| ¿El tratamiento | 0.309063 |
| planta cannabis | 0.341326 |
| potencial alto | 0.304956 |
| medicina complementaria | 0.465284 |
| largo tiempo | 0.303689 |
| ¿el cannabis | 0.355862 |
|
CLICK HERE |
| 3898 |
National Cancer Institute |
Html |
en |
National Cancer Act of 1971 |
The National Cancer Act of 1971, signed into law by President Richard Nixon, established the National Cancer Institute in its current form. |
| local public agencies | 0.263615 |
| National Cancer Advisory | 0.650054 |
| United States Code | 0.285316 |
| presidentially appointed committee | 0.280399 |
| congress | 0.267955 |
| section | 0.313878 |
| members | 0.281565 |
| periodic public hearings | 0.26114 |
| National Advisory Cancer | 0.311011 |
| cancer research effort | 0.272363 |
| National Institutes | 0.423416 |
| President’s Cancer | 0.269099 |
| peer review groups | 0.27756 |
| new cancer program | 0.274372 |
| cancer research data | 0.317718 |
| director | 0.357764 |
| Cancer Conquest Program | 0.270321 |
| Cancer Advisory Council | 0.261669 |
| formal peer review | 0.25641 |
| National Cancer Act | 0.322085 |
| national effort | 0.266101 |
| research data bank | 0.295559 |
| programs | 0.258759 |
| new cancer centers | 0.270844 |
| National Cancer | 0.961422 |
|
| United States | 0.352369 |
| international cancer research | 0.31865 |
| sec. | 0.262726 |
| Advisory Cancer Council | 0.296567 |
| cancer research | 0.391545 |
| new National Cancer | 0.296152 |
| new cancer research | 0.280939 |
| cancer control activities | 0.268219 |
| national program | 0.264635 |
| National Cancer Institute | 0.922231 |
| Cancer Panel | 0.285667 |
| NCI director | 0.269686 |
| health professions personnel | 0.261888 |
| cancer research program | 0.301343 |
| comprehensive national program | 0.262972 |
| comprehensive national plan | 0.253394 |
| Health Service Act | 0.445842 |
| national cancer program | 0.58313 |
| Public Health Service | 0.448514 |
| cancer research activities | 0.2733 |
| Cancer Conquest Agency | 0.262618 |
| annual budget | 0.264713 |
| Cancer Advisory Board | 0.646243 |
| total national commitment | 0.252359 |
|
CLICK HERE |
| 15632 |
National Cancer Institute |
Html |
null |
NCI Grant Application Development, Submission, and Award |
Learn how the six-step process of the NCI grants process works— from application development, to peer review, to post-award administration. |
|
|
CLICK HERE |
| 16844 |
National Cancer Institute |
Html |
en |
Ohio State University and University of Kentucky — Optimizing RNA Nanoparticle's Size and Shape for Enhancing Cancer Targeting and Treatment |
A systematic characterization of RNA nanoparticle behavior, in vitro and in vivo, to optimize its cellular delivery to triple negative breast cancer (TNBC). |
| optimized therapeutic systems | 0.528757 |
| varying shapes | 0.305417 |
| moieties | 0.241586 |
| endosomal escape | 0.300775 |
| RNA nanoparticle behavior | 0.817424 |
| optimum shape | 0.346242 |
| project team | 0.300326 |
| vivo delivery | 0.345174 |
| overall goal | 0.318652 |
| therapeutic components | 0.373072 |
| Jianhua Yu | 0.345836 |
| tumor regression | 0.318722 |
| Enhancing Cancer Targeting | 0.687284 |
| William Carson | 0.342459 |
| internalization/intracellular trafficking | 0.315312 |
| efficient therapeutic delivery | 0.542327 |
| surgical oncology | 0.297773 |
|
| delivery systems | 0.312116 |
| pharmacokinetic profiles | 0.331727 |
| Daniel Pack | 0.340086 |
| Ohio State University | 0.5489 |
| nanoparticle size | 0.433341 |
| gene therapy | 0.299174 |
| RNA nanoparticles | 0.513535 |
| negative breast cancer | 0.501323 |
| facile chemical processing | 0.476016 |
| rna nanoparticle | 0.954079 |
| Principal Investigators | 0.353961 |
| Peixuan Guo | 0.400645 |
| favorable biodistribution | 0.529957 |
| molecular / cell | 0.296003 |
| cancer immunotherapy | 0.325509 |
| systematic studies | 0.315425 |
| systematic characterization | 0.33975 |
|
CLICK HERE |